Impact of combination antibiotic therapy on Quality of Life in Patients with bacterial pneumonia
DOI:
https://doi.org/10.5281/zenodo.22812052Keywords:
bacterial pneumonia, combination antibiotic therapy, quality of life, community-acquired pneumonia, macrolideAbstract
Background: Combination beta-lactam-macrolide therapy is recommended for moderate-to-severe bacterial pneumonia largely on mortality and readmission data, while its effect on patient-reported quality of life is studied far less directly.
Objective: This review synthesizes comparative trial evidence on combination versus monotherapy antibiotic strategy for bacterial pneumonia alongside the separate literature on post-pneumonia quality of life.
Methods: We conducted a narrative synthesis of randomized trials, meta-analyses, and cohorts comparing antibiotic strategies for pneumonia, together with cohorts measuring health-related quality of life after pneumonia.
Findings: Combination therapy reduces 30-day readmission and, in severely ill or atypical-pathogen-infected patients, mortality, with little added benefit in lower-severity populations; quality of life after pneumonia recovers slowly regardless of regimen and is shadowed for up to a year by elevated cardiovascular risk, but no trial has measured quality of life directly as an antibiotic-strategy endpoint.
Conclusions: The case for combination therapy improving quality of life is presently inferential; a trial powered on a validated quality-of-life instrument is needed to close this gap.
References
Jones, B.E., Ramirez, J.A., Oren, E., Soni, N.J., Sullivan, L.R., Restrepo, M.I., et al. (2026) Diagnosis and Management of Community-Acquired Pneumonia in Adults: An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 212(1): 24-44. DOI: 10.1164/rccm.202507-1692ST
Martin-Loeches, I., Torres, A., Nagavci, B., Aliberti, S., Antonelli, M., Bassetti, M., et al. (2023) ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Medicine, 49(6): 615-632. DOI: 10.1007/s00134-023-07033-8
Fine, M.J., Auble, T.E., Yealy, D.M., Hanusa, B.H., Weissfeld, L.A., Singer, D.E., et al. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine, 336(4): 243-250. DOI: 10.1056/NEJM199701233360402
Lim, W.S., van der Eerden, M.M., Laing, R., Boersma, W.G., Karalus, N., Town, G.I., et al. (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax, 58(5): 377-382. DOI: 10.1136/thorax.58.5.377
Lim, W.S., Baudouin, S.V., George, R.C., Hill, A.T., Jamieson, C., Le Jeune, I., et al. (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax, 64(Suppl 3): iii1-iii55. DOI: 10.1136/thx.2009.121434
Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases, 44(Suppl 2): S27-S72. DOI: 10.1086/511159
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. (2011) Guidelines for the management of adult lower respiratory tract infections - full version. Clinical Microbiology and Infection, 17(Suppl 6): E1-E59. DOI: 10.1111/j.1469-0691.2011.03672.x
Postma, D.F., van Werkhoven, C.H., van Elden, L.J., Thijsen, S.F., Hoepelman, A.I., Kluytmans, J.A., et al. (2015) Antibiotic treatment strategies for community-acquired pneumonia in adults. New England Journal of Medicine, 372(14): 1312-1323. DOI: 10.1056/NEJMoa1406330
Garin, N., Genné, D., Carballo, S., Chuard, C., Eich, G., Hugli, O., et al. (2014) β-lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Internal Medicine, 174(12): 1894-1901. DOI: 10.1001/jamainternmed.2014.4887
Asadi, L., Sligl, W.I., Eurich, D.T., Colmers, I.N., Tjosvold, L., Marrie, T.J., et al. (2012) Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clinical Infectious Diseases, 55(3): 371-380. DOI: 10.1093/cid/cis414
Prizão, V.M., Martins, O.C., de Athayde de Hollanda Morais, B.A., Mendes, B.X., Defante, M.L.R., Souza, M.M. (2025) Effectiveness of macrolides as add-on therapy to beta-lactams in community-acquired pneumonia: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 81(1): 83-91. DOI: 10.1007/s00228-024-03775-6
Nakashima, K., Aoshima, M., Matsui, H., Shiraishi, A., Ito, H., Suzuki, M., et al. (2025) Beta-lactam plus macrolide treatment versus beta-lactam monotherapy for community-acquired pneumonia: a propensity score analysis using data from a multicenter prospective cohort study. BMC Infectious Diseases, 26: 216. DOI: 10.1186/s12879-025-12408-x
Metlay, J.P., Atlas, S.J., Borowsky, L.H., Singer, D.E. (1997) Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. Journal of General Internal Medicine, 12(7): 423-430. DOI: 10.1046/j.1525-1497.1997.00074.x
el Moussaoui, R., Opmeer, B.C., de Borgie, C.A., Nieuwkerk, P., Bossuyt, P.M., Speelman, P., et al. (2006) Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia. Chest, 130(4): 1165-1172. DOI: 10.1378/chest.130.4.1165
el Moussaoui, R., de Borgie, C.A., van den Broek, P., Hustinx, W.N., Bresser, P., van den Berk, G.E., et al. (2006) Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ, 332(7554): 1355. DOI: 10.1136/bmj.332.7554.1355
Ryrsø, C.K., Hegelund, M.H., Faurholt-Jepsen, D., Dungu, A.M., Ritz, C., Olsen, M.F., et al. (2026) Health-related quality of life in community-acquired pneumonia: a prospective cohort study. Scientific Reports, 16: 28640. DOI: 10.1038/s41598-026-59119-0
Hegelund, M.H., Jagerova, L., Olsen, M.F., Ryrsø, C.K., Ritz, C., Dungu, A.M., et al. (2024) Health-related quality of life predicts prognosis in individuals with COPD hospitalized with community-acquired pneumonia - a prospective cohort study. Scientific Reports, 14: 27315. DOI: 10.1038/s41598-024-74933-0
Holter, J.C., Ueland, T., Jenum, P.A., Müller, F., Brunborg, C., Frøland, S.S., et al. (2016) Risk factors for long-term mortality after hospitalization for community-acquired pneumonia: a 5-year prospective follow-up study. PLOS ONE, 11(2): e0148741. DOI: 10.1371/journal.pone.0148741
Yende, S., D'Angelo, G., Kellum, J.A., Weissfeld, L., Fine, J., Welch, R.D., et al. (2008) Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. American Journal of Respiratory and Critical Care Medicine, 177(11): 1242-1247. DOI: 10.1164/rccm.200712-1777OC
Corrales-Medina, V.F., Alvarez, K.N., Weissfeld, L.A., Angus, D.C., Chirinos, J.A., Chang, C.C., et al. (2015) Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA, 313(3): 264-274. DOI: 10.1001/jama.2014.18229
Tralhão, A., Póvoa, P. (2020) Cardiovascular events after community-acquired pneumonia: a global perspective with systematic review and meta-analysis of observational studies. Journal of Clinical Medicine, 9(2): 414. DOI: 10.3390/jcm9020414
Musher, D.M., Thorner, A.R. (2014) Community-acquired pneumonia. New England Journal of Medicine, 371(17): 1619-1628. DOI: 10.1056/NEJMra1312885
Welte, T., Torres, A., Nathwani, D. (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax, 67(1): 71-79. DOI: 10.1136/thx.2009.129502
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Davide Ferrari, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
